December 16, 2025

Aptamer Group signs first licensing deal with Twist Bioscience

Aptamer Group has entered into its first licensing agreement with Twist Bioscience, granting a non-exclusive licence for the use of an Optimer® binder in hot-start PCR and next-generation sequencing products...

PPHE Hotel Group refinances Park Plaza Victoria London

PPHE Hotel Group has agreed a new £88 million refinancing facility for Park Plaza Victoria London, replacing an existing loan due to mature in early 2026...

Greggs Plc appoints Richard Smothers as Non-Executive Director

Greggs plc has announced the appointment of Richard Smothers as an independent Non-Executive Director, effective from 1 February 2026...

Hollywood Bowl Group reports FY2025 results with revenue growth

Hollywood Bowl Group has published its audited results for the year ended 30 September 2025, reporting revenue growth of 8.8% to £250.7m and a fourth consecutive year of record revenue and adjusted EBITDA...

Centrica Plc agrees sale of Spirit Energy assets to Serica

Centrica has announced the sale of Spirit Energy’s remaining interests in the Cygnus gas field and other producing assets in the Southern North Sea to Serica Energy...

AstraZeneca’s Enhertu plus pertuzumab approved in US for 1st-line HER2-positive breast cancer

AstraZeneca and Daiichi Sankyo have received US FDA approval for Enhertu in combination with pertuzumab as a 1st-line treatment for adults with unresectable or metastatic HER2-positive breast cancer...

GSK Plc secures UK approval for Exdensur in asthma and nasal polyps

GSK has announced that Exdensur (depemokimab) has received marketing authorisation from the UK MHRA for use in certain asthma and chronic rhinosinusitis with nasal polyps patients...

Anglo American and Teck secure Canadian approval for merger

Anglo American and Teck Resources have received approval from the Government of Canada under the Investment Canada Act for their proposed merger of equals...

Manx Financial Group issues new shares following RSU vesting

Manx Financial has announced the exercise of Restricted Stock Units over 2,072,500 new ordinary shares at nil cost. The share issues relate to vested awards granted in November 2023 and include allocations to directors and a PDMR, with admission to trading on AIM expected on 23 December 2025...

Time Finance reports H1 2025/26 trading update with profit growth

The AIM listed finance provider recorded higher new business origination, an expanded lending book, and increased profit before tax, alongside lower arrears and write-offs, supporting confidence that full year performance will be in line with market guidance...
Search

Funds

September 13, 2023

Aptamer Group signs first licensing deal with Twist Bioscience

Aptamer Group has entered into its first licensing agreement with Twist Bioscience, granting a non-exclusive licence for the use of an Optimer® binder in hot-start PCR and next-generation sequencing products...

PPHE Hotel Group refinances Park Plaza Victoria London

PPHE Hotel Group has agreed a new £88 million refinancing facility for Park Plaza Victoria London, replacing an existing loan due to mature in early 2026...

Greggs Plc appoints Richard Smothers as Non-Executive Director

Greggs plc has announced the appointment of Richard Smothers as an independent Non-Executive Director, effective from 1 February 2026...

Hollywood Bowl Group reports FY2025 results with revenue growth

Hollywood Bowl Group has published its audited results for the year ended 30 September 2025, reporting revenue growth of 8.8% to £250.7m and a fourth consecutive year of record revenue and adjusted EBITDA...

Centrica Plc agrees sale of Spirit Energy assets to Serica

Centrica has announced the sale of Spirit Energy’s remaining interests in the Cygnus gas field and other producing assets in the Southern North Sea to Serica Energy...

AstraZeneca’s Enhertu plus pertuzumab approved in US for 1st-line HER2-positive breast cancer

AstraZeneca and Daiichi Sankyo have received US FDA approval for Enhertu in combination with pertuzumab as a 1st-line treatment for adults with unresectable or metastatic HER2-positive breast cancer...

GSK Plc secures UK approval for Exdensur in asthma and nasal polyps

GSK has announced that Exdensur (depemokimab) has received marketing authorisation from the UK MHRA for use in certain asthma and chronic rhinosinusitis with nasal polyps patients...

Anglo American and Teck secure Canadian approval for merger

Anglo American and Teck Resources have received approval from the Government of Canada under the Investment Canada Act for their proposed merger of equals...

Manx Financial Group issues new shares following RSU vesting

Manx Financial has announced the exercise of Restricted Stock Units over 2,072,500 new ordinary shares at nil cost. The share issues relate to vested awards granted in November 2023 and include allocations to directors and a PDMR, with admission to trading on AIM expected on 23 December 2025...

Time Finance reports H1 2025/26 trading update with profit growth

The AIM listed finance provider recorded higher new business origination, an expanded lending book, and increased profit before tax, alongside lower arrears and write-offs, supporting confidence that full year performance will be in line with market guidance...
Search

Funds

December 16, 2025

FTSE 100

Funds